Certified by Founder
Lodge
smartbax
start up
Germany
- München
- 24/05/2023
- Seed
- $1,291,000
smartbax develops novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. With the first-in-class compounds, the company targets the multi-drug resistant pathogens methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
- Industry Biotechnology Research
- Website https://www.smartbax.de/
- LinkedIn https://www.linkedin.com/company/smartbax-gmbh/
Iridius | $8,600,000 | (Apr 28, 2026)
Audion | $15,000,000 | (Apr 28, 2026)
Decade Energy | $25,763,540 | (Apr 28, 2026)
TriFetch | $1,900,000 | (Apr 28, 2026)
SquareMind | $18,000,000 | (Apr 28, 2026)
Linexa | $2,342,840 | (Apr 28, 2026)
HrFlow.ai | $7,000,000 | (Apr 28, 2026)
Cnuic Technologies | $3,000,000 | (Apr 28, 2026)
Zócalo Health | $15,000,000 | (Apr 24, 2026)
VREY | $3,859,432 | (Apr 24, 2026)
QMatter | $1,200,000 | (Apr 24, 2026)